Perspective Therapeutics (CATX) Profit After Tax (2010 - 2026)

Perspective Therapeutics has disclosed Profit After Tax across 17 years of filings, most recently posting -$26.2 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$26.2 million, down 44.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$111.1 million (down 30.48% YoY), and the FY2025 annual result was -$103.1 million, down 30.07% from the prior year.
• Profit After Tax came in at -$26.2 million for Q1 2026 at Perspective Therapeutics, up from -$37.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$371000.0 in Q1 2023 to a low of -$40.2 million in Q4 2024.
• The 5-year median for Profit After Tax is -$12.3 million (2024), against an average of -$15.9 million.
• Across the five-year window, Profit After Tax jumped 72.46% in 2023 and plunged 3211.05% in 2024, its largest moves.
• Perspective Therapeutics' Profit After Tax stood at -$7.3 million in 2022, then sank by 236.4% to -$24.7 million in 2023, then plunged by 62.79% to -$40.2 million in 2024, then advanced by 6.67% to -$37.5 million in 2025, then jumped by 30.14% to -$26.2 million in 2026.
• The last three Profit After Tax figures came in at -$26.2 million (Q1 2026), -$37.5 million (Q4 2025), and -$26.0 million (Q3 2025), per Business Quant data.